Antiangiogenic Therapy Escape A retrospective analysis in patients with malignant glioma who were treated with a second-line regimen containing bevacizumab after failure of treatment with an ...

New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination ...

These findings underscore the importance of biomarkers that would predict whether a patient will respond to, and monitor the efficacy of or the resistance to, antiangiogenic therapy.

Tumor therapy has evolved significantly over recent decades, yet tumors continue to develop resistance to conventional ...

President Donald Trump has signed House Resolution 1 (H.R. 1), the final version of which does not impose a moratorium on state legislation governing the use of AI. The bill does, however, restore the ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

China NMPA accepts CARsgen Therapeutics’ NDA for satri-cel to treat Claudin18.2-positive advanced G/GEJA: Shanghai, China Friday, June 27, 2025, 12:00 Hrs [IST] CARsgen Therapeu ...

Advancements in polymer science are transforming the retinal disease treatment landscape, addressing clinical challenges such ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

Bone and Cancer Working Group has released a comprehensive review detailing the often under-recognized impact of modern anti-cancer treatments on bone health.